NLRP3 and atherosclerosis: Knockdown of NLRP3 or inhibition of the ERK/p38 pathway effectively reversed the effects of HHcy on VSMC dedifferentiation, highlighting the therapeutic potential of SXBX in managing HHcy-induced atherosclerosis [139].